Beranda49B • FRA
add
Beigene Ltd
Tutup sebelumnya
€16,70
Rentang hari
€17,20 - €17,20
Rentang tahun
€8,90 - €20,20
Kapitalisasi pasar
216,33 M HKD
Volume Rata-Rata
7,00
Rasio P/E
-
Hasil dividen
-
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,19 M | 84,84% |
Biaya operasional | 1,09 M | 19,51% |
Laba bersih | -139,70 jt | 58,27% |
Margin laba bersih | -11,75 | 77,43% |
Penghasilan per saham | -0,80 | -196,59% |
EBITDA | -33,25 jt | 90,73% |
Tarif pajak efektif | -112,84% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 2,63 M | -17,16% |
Total aset | 5,92 M | 1,99% |
Total liabilitas | 2,59 M | 14,14% |
Total ekuitas | 3,33 M | — |
Saham yang beredar | 106,72 jt | — |
Harga terhadap nilai buku | 0,53 | — |
Tingkat pengembalian aset | -3,26% | — |
Tingkat pengembalian modal | -4,29% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -139,70 jt | 58,27% |
Kas dari operasi | 111,61 jt | 128,21% |
Kas dari investasi | -247,31 jt | 26,86% |
Kas dari pembiayaan | 30,05 jt | -92,11% |
Perubahan kas bersih | -155,64 jt | 57,59% |
Arus kas bebas | 434,97 jt | 505,95% |
Tentang
BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has offices in North America, Europe, South America, Asia and Australia. BeiGene has a large presence in the Chinese market. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November, 2024 the company announced its intention to rebrand as BeOne Medicines. Wikipedia
Didirikan
28 Okt 2010
Situs
Karyawan
11.000
